20.06.2019 20:09

Helius Medical Technologies to talk science behind PoNSTM device at Rehab Week

A breakthrough in the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury

TORONTO, June 20, 2019 /CNW/ - Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, will be hosting a scientific lecture at the fourth-annual Rehab Week, a global cross-disciplinary conference among engineers, researchers and clinicians in the field of rehabilitation technology. The lecture, which will be offered twice during Rehab week, will provide an overview of a new, non-invasive treatment option in Canada for those suffering from chronic balance deficit as a result of mild-to-moderate traumatic brain injury.

Approximately 350,000 people in Canada are living with a chronic balance deficit following a mild-to-moderate traumatic brain injury (mmTBI), and an estimated 13,000 new cases are reported annually. A recent publication revealed that, in Ontario alone, previously unreported/hidden health costs related to mild TBI is in excess of $110 million each year. Symptoms of mmTBI can negatively impact an individual's daily life, from difficulty walking to loss of balance and coordination. As a means to improve treatment of chronic balance deficit, Helius developed  the Portable Neuromodulation Stimulator (PoNS™),* a device authorized for sale in Canada. The PoNS™ device delivers mild stimulation to nerves in the tongue, which connect to the brain. This stimulation, combined with targeted physiotherapy, is believed to promote neuroplasticity, which may provide functional improvements in balance and mobility.

"The challenge has been that with the current standard of care – rehabilitative physical therapy – as many as 40% of patients continue to experience balance issues," said Dr. Kim Skinner, Director of Physical Therapy at Helius and a former director of physical therapy and researcher at the University of Wisconsin. "PoNS is the first patented, non-invasive device designed to amplify the brain's powerful ability to heal itself. When used in conjunction with physical therapy, PoNS™ has the potential to help restore balance and gait for patients who have suffered mild-to-moderate traumatic brain injuries, including concussions."

Dr. Skinner, who worked with the lab team that developed PoNSTM, will provide insight into clinical trials which resulted in nearly 70% of patients experiencing significant improvements in their balance. In a 14 week long-term treatment trial, this benefit persisted for at least 12 weeks following the end of PoNS Treatment™.

"Helius has established a network of neuro-rehabilitation clinics in Canada that are authorized and trained to provide PoNS Treatment," said Phil Deschamps, CEO, Helius Medical Technologies. "Canadians who have chronic balance deficit previously had limited therapeutic options. With PoNSTM, there is now a new treatment available in Canada that may improve their balance and mobility."

For more information about PoNSTM, visit

Helius is a silver sponsor of Rehab Week, taking place June 24-28 at the Metro Toronto Convention Centre.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company's purpose is to develop, license and acquire unique and non-invasive platform technologies that may amplify the brain's ability to heal itself. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit

*About the PoNS Device and PoNS Treatment™

The Portable Neuromodulation Stimulator (PoNS™) is a licensed class II, noninvasive, medical device in Canada intended for use as an acute treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy. The device is limited to prescription use. PoNS™ is an investigational medical device in the United States, the European Union ("EU"), and Australia ("AUS"), and it is currently under review for clearance by an EU Notified Body and the AUS Therapeutic Goods Administration. PoNS Treatment™ is currently not commercially available in the United States, the European Union or Australia.

Cautionary Disclaimer Statement:

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as "believe," "continue," "look forward," "will" and similar expressions. Such forward-looking statements include, among others, statements regarding the Company's future clinical and regulatory development plans for the PoNS device, including the planned physical therapy only study, and the potential regulatory clearance of the PoNS device.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the uncertainties associated with the regulation of commercially available medical devices in Canada, including Health Canada's ongoing assessment of post-market data, the initiation and enrollment process for the planned physical therapy only study, the clinical development, regulatory submission and approval process in the United States, the European Union and Australia, as well as the Company's capital requirements needed to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators, and including the risks and uncertainties about the Company's business described in the "Risk Factors" sections of the Company's Annual Report on Form 10-K for the year ended December 31, 2018, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at or

The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

SOURCE Helius Medical Technologies, Inc.

Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX geht etwas fester ins Wochenende -- Dow Jones im Minus -- Wirecard: Zusammenarbeit mit Aldi -- Zipse wird neuer BMW-Vorstandschef -- Software AG, Bayer, Sartorius, Microsoft, Boeing im Fokus

Pfeiffer Vacuum passt Prognose nach Quartalszahlen an. American Express meldet Gewinnsprung. Ex-Automanager Ghosn reicht Klage gegen Nissan und Mitsubishi ein. NORMA passt Jahresprognose an. Heidelberger Druck-Aktien setzen Kurseinbruch fort. AB InBev verkauft Australien-Geschäft. Munich Re erzielt Milliarden-Gewinn.

Die 5 beliebtesten Top-Rankings

Die 12 toten Topverdiener 2019
Diese Legenden sind die bestbezahlten Toten der Welt
Das hat sich geändert
Diese Aktien hat George Soros im Depot
In welchen Ländern kostet der Big Mac wie viel?
Die Länder mit den größten Goldreserven 2019
Wer lagert das meiste Gold?
In diesen Berufen bekommt man das niedrigste Gehalt
Welche Branchen man besser meiden sollte.
mehr Top Rankings


Wo sehen Sie den DAX Ende 2019?

Online Brokerage über Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von!


Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Euro US-Dollar
Microsoft Corp.870747
Deutsche Bank AG514000
Scout24 AGA12DM8
Daimler AG710000
Apple Inc.865985
Sixt SE St.723132
BMW AG519000
Canada Carbon IncA1J5XH
AbbVie IncA1J84E
Watsco Inc.885676
ExxonMobil Corp. (Exxon Mobil)852549